Can tebentafusp and SBRT control disease in uveal melanoma?
Tebentafusp is a targeted immunotherapy for uveal melanoma that has spread, but it only works in patients with a specific HLA type (HLA-A*02:01). Stereotactic body radiotherapy (SBRT) is a precise, high-dose radiation treatment. A recent case report suggests that combining tebentafusp with SBRT may help control the disease when it starts to progress in a single spot. However, this is based on one patient's experience, not a large study.
What the research says
A network meta-analysis of 16 trials found that tebentafusp improved overall survival (OS) in metastatic uveal melanoma, but it had the worst progression-free survival (PFS) among the treatments studied 1. This means that while patients may live longer, the disease can still progress. In contrast, liver-directed therapy combined with immune checkpoint inhibitors showed the best OS and PFS 1.
A case report describes a 39-year-old woman with metastatic uveal melanoma who was treated with tebentafusp 25. After four months, she had progression in one lymph node (oligoprogression), while liver lesions were stable. She then received SBRT (30 Gy in 10 fractions) to that node while continuing tebentafusp 25. Nine months later, MRI showed a partial response in all lesions, and she maintained disease control for an additional 35 months with excellent quality of life 25. This suggests that adding SBRT to tebentafusp may help control disease when only a few spots progress.
A phase 2 trial (NCT03070392) compared tebentafusp (IMCgp100) to investigator's choice of dacarbazine, ipilimumab, or pembrolizumab in HLA-A*02:01 positive patients with advanced uveal melanoma 4. The primary outcome was overall survival, and results showed improved OS with tebentafusp 4. However, this trial did not combine tebentafusp with radiation.
Another study on immunoembolization (a liver-directed therapy) for liver-dominant metastatic uveal melanoma reported a disease control rate of 67.4% 3. This is lower than the disease control seen in the FOCUS trial using melphalan via percutaneous hepatic perfusion 3. This highlights that different treatments have varying effectiveness, and combining therapies may be needed for better control.
What to ask your doctor
- Am I HLA-A*02:01 positive? Tebentafusp only works in patients with this genetic marker.
- If I have only a few spots of progression on tebentafusp, could adding SBRT be an option for me?
- What are the potential side effects of combining tebentafusp with radiation therapy?
- Are there any clinical trials testing tebentafusp plus SBRT or other radiation approaches for uveal melanoma?
- How does my overall health and disease pattern affect whether this combination might be suitable?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.